Quick Answer
Revolution Medicines, Inc. reported Total Revenue of $0.00 for the year ending 2025.
- This data is from Revolution Medicines, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $13.17 million | Q2 2019: $12.28 million | Q3 2019: $12.51 million | Q4 2019: $12.09 million | Q1 2020: $11.55 million | Q2 2020: $10.03 million | Q3 2020: $12.66 million | Q4 2020: $8.75 million | Q1 2021: $10.13 million | Q2 2021: $8.70 million | Q3 2021: $1.10 million | Q1 2022: $7.58 million | Q2 2022: $9.12 million | Q3 2022: $3.36 million | Q1 2023: $7.01 million | Q2 2023: $3.82 million | Q3 2023: $0.00 | Q1 2024: $0.00 | Q2 2024: $0.00 | Q3 2024: $0.00.
- Over the full 8 years of available data (2018 to 2025), Revolution Medicines, Inc.'s Total Revenue has declined by 100.0%.
- Historical annual values: Fiscal year 2025: $0.00 | Fiscal year 2024: $0.00 | Fiscal year 2023: $11.58 million | Fiscal year 2022: $35.38 million | Fiscal year 2021: $29.39 million | Fiscal year 2020: $42.98 million | Fiscal year 2019: $50.04 million | Fiscal year 2018: $20.17 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: